LARIMAR THERAPEUTICS, INC. Operating Lease Right-of-Use Assets
LARIMAR THERAPEUTICS, INC. (LRMR) had Operating Lease Right-of-Use Assets of $3.06 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-04
- 2026-06-30: Operating Lease, Right-of-Use Asset $3.06M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $1.87M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $2.07M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $2.27M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $3.06M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.87M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $2.07M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $2.27M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $2.47M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $2.65M 10-Q · filed 2025-04-30 | |
| 2024-12-31 | $2.84M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $3.03M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $3.21M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $2.92M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $3.08M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $2.90M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $2.58M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $2.72M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $2.86M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $3.00M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $3.13M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $3.27M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $3.41M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $3.54M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $3.67M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $3.81M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $3.94M 10-K · filed 2022-03-25 | |
| 2020-09-30 | $4.09M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $4.25M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $6.93M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $87.00K 10-K · filed 2021-03-04 | $7.05M 10-K · filed 2020-03-05 |
| 2019-09-30 | $7.17M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $7.34M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $883.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |